Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance

Danish pharmaceutical giant Novo Nordisk revised down its full-year sales and profit guidance, primarily due to weaker U.S. growth expectations for its key weight-loss drug Wegovy and diabetes treatment Ozempic. The company specifically cited persistent use of compounded GLP-1s, slower market expansion, and competition impacting Wegovy's U.S. outlook. This guidance cut led to a 15% drop in Novo Nordisk's shares.

Analysis

Novo Nordisk has materially revised its full-year sales and profit guidance downward, triggering a significant 15% decline in its share price. The adjustment is directly attributed to a weakened outlook for its key GLP-1 drugs, Wegovy and Ozempic, specifically within the critical U.S. market. The company has explicitly identified three primary headwinds affecting its Wegovy sales forecast: the persistent market presence of compounded GLP-1 alternatives, a slower-than-anticipated expansion of the overall obesity drug market, and intensifying competition. This development suggests that the previously robust growth narrative for Novo Nordisk's obesity and diabetes franchise is facing substantial near-term challenges, forcing a fundamental repricing of the company's growth expectations by the market.

Key Decisions for Investors

• Investors should immediately reassess their valuation models for Novo Nordisk, as the guidance cut signals that the high-growth assumptions for the U.S. market are no longer tenable.
• It is now critical to monitor competitive intelligence on the market share of compounded GLP-1s and rival products, as these have been confirmed as primary drivers of the sales slowdown.
• Given the sharp negative market reaction and newly introduced uncertainties, investors may consider trimming long positions or hedging against further downside until the company provides greater clarity on its strategy to navigate these competitive and market expansion challenges.